Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab.

IF 5.5 4区医学 Q1 DERMATOLOGY

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-05-02 DOI:10.1111/ddg.15688

Hanwen Wu, Jiling Zhu, Nali Yang, Xiaolin Ji, Zhenyan Li, Yiwen Zhou, Qiuyang Xu, Yahui Ye, Zicheng Bai, Jingying Wang, Zhiming Li

{"title":"Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab.","authors":"Hanwen Wu, Jiling Zhu, Nali Yang, Xiaolin Ji, Zhenyan Li, Yiwen Zhou, Qiuyang Xu, Yahui Ye, Zicheng Bai, Jingying Wang, Zhiming Li","doi":"10.1111/ddg.15688","DOIUrl":null,"url":null,"abstract":"Background and objectives: In the clinical management of atopic dermatitis (AD), treatment discontinuations and subsequent disease relapse are common. Understanding relapse patterns following treatment discontinuation in AD patients is therefore essential. This study aims to investigate the time to relapse and identify predictive factors in patients with moderate-to-severe AD who responded to treatment with selective Janus kinase 1 (JAK1) inhibitors (upadacitinib or abrocitinib) or dupilumab.Patients and methods: This single-center, retrospective cohort analysis reviewed the data for patients aged ≥ 12 years with moderate-to-severe AD who responded to either JAK1 inhibitors or dupilumab within 16 weeks. The primary outcome measures included the median time to skin lesion relapse after treatment discontinuation. Additionally, predictors for relapse were explored.Results: Within 72 weeks after discontinuation, the median time to skin lesion relapse after discontinuation for JAK1 inhibitor and dupilumab responders was 60 and 457 days, respectively. Overall, 52.9% and 34.6% of patients who used JAK1 inhibitors and dupilumab reported AD skin lesion relapse (average hazard ratio = 2.58, 95% confidence interval: 1.25-5.33, p = 0.01). No other factors influencing AD relapse were identified.Conclusions: After treatment discontinuation, Dupilumab showed relatively longer efficacy than JAK1 inhibitors, resulting in a lower risk of relapse.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Der Deutschen Dermatologischen Gesellschaft","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ddg.15688","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: In the clinical management of atopic dermatitis (AD), treatment discontinuations and subsequent disease relapse are common. Understanding relapse patterns following treatment discontinuation in AD patients is therefore essential. This study aims to investigate the time to relapse and identify predictive factors in patients with moderate-to-severe AD who responded to treatment with selective Janus kinase 1 (JAK1) inhibitors (upadacitinib or abrocitinib) or dupilumab.

Patients and methods: This single-center, retrospective cohort analysis reviewed the data for patients aged ≥ 12 years with moderate-to-severe AD who responded to either JAK1 inhibitors or dupilumab within 16 weeks. The primary outcome measures included the median time to skin lesion relapse after treatment discontinuation. Additionally, predictors for relapse were explored.

Results: Within 72 weeks after discontinuation, the median time to skin lesion relapse after discontinuation for JAK1 inhibitor and dupilumab responders was 60 and 457 days, respectively. Overall, 52.9% and 34.6% of patients who used JAK1 inhibitors and dupilumab reported AD skin lesion relapse (average hazard ratio = 2.58, 95% confidence interval: 1.25-5.33, p = 0.01). No other factors influencing AD relapse were identified.

Conclusions: After treatment discontinuation, Dupilumab showed relatively longer efficacy than JAK1 inhibitors, resulting in a lower risk of relapse.

查看原文本刊更多论文

停药后特应性皮炎复发和复发的预测因素：JAK1抑制剂与dupilumab。

背景与目的：在特应性皮炎（AD）的临床治疗中，治疗中断和随后的疾病复发是常见的。因此，了解阿尔茨海默病患者停止治疗后的复发模式至关重要。本研究旨在调查选择性JAK1 （JAK1）抑制剂（upadacitinib或abrocitinib）或dupilumab治疗有反应的中重度AD患者的复发时间并确定预测因素。患者和方法：这项单中心、回顾性队列分析回顾了年龄≥12岁的中度至重度AD患者的数据，这些患者在16周内对JAK1抑制剂或dupilumab有反应。主要结局指标包括停药后皮肤病变复发的中位时间。此外，还探讨了复发的预测因素。结果：停药后72周内，JAK1抑制剂和dupilumab应答者停药后皮肤病变复发的中位时间分别为60天和457天。总体而言，52.9%和34.6%使用JAK1抑制剂和dupilumab的患者报告AD皮肤病变复发（平均风险比= 2.58,95%可信区间：1.25-5.33,p = 0.01）。未发现影响AD复发的其他因素。结论：停药后，Dupilumab比JAK1抑制剂的疗效相对较长，复发风险较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal Der Deutschen Dermatologischen Gesellschaft 医学-皮肤病学

CiteScore

3.50

自引率

25.00%

发文量

406

审稿时长

1 months

期刊介绍： The JDDG publishes scientific papers from a wide range of disciplines, such as dermatovenereology, allergology, phlebology, dermatosurgery, dermatooncology, and dermatohistopathology. Also in JDDG: information on medical training, continuing education, a calendar of events, book reviews and society announcements. Papers can be submitted in German or English language. In the print version, all articles are published in German. In the online version, all key articles are published in English.